Shares of Lexicon Pharmaceuticals LXRX have jumped 30% after signing a licensing deal for its pre-clinical obesity drug ...

A Houston-area company has just inked a massive, $1 billion deal to become the next big weight-loss medication maker. Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will ...

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for the preclinical obesity drug LX9851. The company abandoned its underperforming heart failure drug and ...

Novo Nordisk has entered into an exclusive license agreement with Lexicon Pharmaceuticals Inc. for LX9851, a first-in-class, oral non-incretin development candidate in obesity and associated metabolic ...

As uncertainties surrounding trade policies, fresh recession fears, and persistent inflation kept the markets on tenterhooks throughout the past week, a handful of small-caps defied the odds by ...

The small-molecule candidate, LX9851, is designed to increase the feeling of fullness by inhibiting ACSL5. Lexicon targeted the enzyme after finding that knocking out its gene resulted in mice ...

Lexicon Pharmaceuticals (LXRX) announced that it has entered into an exclusive license agreement with Novo Nordisk (NVO) for LX9851, a ...

Shares of Lexicon Pharmaceuticals LXRX have jumped 30% after signing a licensing deal for its pre-clinical obesity drug LX9851 with pharma giant Novo Nordisk NVO last week. Per the deal terms ...

Under the terms of the agreement, Novo Nordisk obtains an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. Lexicon will be responsible for ...